Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-NIS in recurrent or refractory multiple myeloma
NCT00450814Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2006
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of MV-NIS in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Number of Phase I Participants With Dose-Limiting Toxicity Events at 6 weeks. Started Nov 2006; status: completed.
02
Drugs
MV-NIS
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00450814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450814.